ARVN - ARVINAS, INC.
IEX Last Trade
18.69
-6.310 -33.761%
Share volume: 0
Last Updated: Tue 24 Dec 2024 06:15:37 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
19.80%
PREVIOUS CLOSE
CHG
CHG%
$25.00
-6.31
-25.24%
Fundamental analysis
30%
Profitability
25%
Dept financing
26%
Liquidity
75%
Performance
25%
Performance
5 Days
1.35%
1 Month
-25.53%
3 Months
-20.84%
6 Months
-23.43%
1 Year
-52.75%
2 Year
-42.72%
Key data
Stock price
$18.69
DAY RANGE
$18.10 - $25.00
52 WEEK RANGE
$18.60 - $53.08
52 WEEK CHANGE
-$55.75
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
Company detail
CEO: John G. Houston
Region: US
Website: arvinas.com
Employees: 420
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: arvinas.com
Employees: 420
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Arvinas, Inc. engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC)
Recent news